Ashurst

The rancour is rising between Care A2 Plus and its US business partner Gensco Pharma, with the infant formula company firing off a cross-claim in a lawsuit alleging it breached a lucrative distribution deal.

Federal environment minister Tanya Plibersek’s decision to greenlight the expansion of two mega coal mines in NSW was contrary to findings by the “entire community of climate scientists around the globe”, a court has heard. 

A judge has questioned an argument by Optus that a report by Deloitte into a major data breach was protected by privilege, saying a press release by the teleco’s boss belied the claim that the provision of legal advice was the report’s chief purpose.

The OAIC has been dragged to court by the law firm that filed a class action-style complaint over the massive Optus data breach, after the privacy commissioner chose a competing representative complaint to move forward.

While the use of artificial intelligence is becoming more commonplace in law firms, it has not yet transformed the practice of law, with lawyers reporting that concerns about privacy, reliability, and liability mean the application of AI remains limited.

A battle with the competition regulator over the proposed ANZ, Suncorp tie-up has begun, with the first clash involving a group of rival lenders that want their submissions to the ACCC kept under lock and key.

Global law firm Jones Day has recruited two partners for its growing energy practice, including a former Ashurst partner.

A former Qantas customer service manager can’t undo a $75,000 settlement she reached to resolve a workers compensation claim in order to pursue a discrimination suit against the airline, a court has found.

South Australian MP Rebekha Sharkie has been hit with an employment suit by a former staffer who says she was subjected to “a course of bullying behaviour” by the MP that culminated in a stress-related hospitalisation and left her unable to work.

Novartis has lost its bid to have Pharmacor’s claim that its patent for a blood pressure drug is invalid decided ahead of a main trial where the Swiss pharmaceutical giant will allege the generic drug maker is threatening to infringe its patent.